These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 18609099)

  • 1. Urinary osteocalcin and other markers of bone metabolism: the effect of risedronate therapy.
    Kumm J; Ivaska KK; Rohtla K; Vaananen K; Tamm A
    Scand J Clin Lab Invest; 2008; 68(6):459-63. PubMed ID: 18609099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical usefulness of measurements of urinary deoxypyridinoline (DPD) in patients with postmenopausal osteoporosis receiving intermittent cyclical etidronate: advantage of free form of DPD over total DPD in predicting treatment efficacy.
    Kitatani K; Nakatsuka K; Naka H; Miki T; Morii H; Nishizawa Y
    J Bone Miner Metab; 2003; 21(4):217-24. PubMed ID: 12811626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of risedronate treatment on serum osteoprotegerin and bone marker levels in postmenopausal women with osteoporosis.
    Karadag-Saygi E; Akyuz G; Bizargity P; Ay P
    Gynecol Endocrinol; 2011 Dec; 27(12):1033-6. PubMed ID: 21627558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use: the OFELY study.
    Garnero P; Mulleman D; Munoz F; Sornay-Rendu E; Delmas PD
    J Bone Miner Res; 2003 Oct; 18(10):1789-94. PubMed ID: 14584889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical markers of bone metabolism and prediction of fracture in elderly women.
    Gerdhem P; Ivaska KK; Alatalo SL; Halleen JM; Hellman J; Isaksson A; Pettersson K; Väänänen HK; Akesson K; Obrant KJ
    J Bone Miner Res; 2004 Mar; 19(3):386-93. PubMed ID: 15040826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of vitamin K2 treatment on carboxylation of osteocalcin in early postmenopausal women.
    Yasui T; Miyatani Y; Tomita J; Yamada M; Uemura H; Miura M; Irahara M
    Gynecol Endocrinol; 2006 Aug; 22(8):455-9. PubMed ID: 17012108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring of Risedronate by biochemical bone markers in clinical practice.
    Bunyaratavej N
    J Med Assoc Thai; 2005 Oct; 88(suppl 5):S34-6. PubMed ID: 17500121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of risedronate on biochemical marker of bone resorption in postmenopausal women with osteoporosis or osteopenia.
    Dane C; Dane B; Cetin A; Erginbas M
    Gynecol Endocrinol; 2008 Apr; 24(4):207-13. PubMed ID: 18382907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of type I collagen C telopeptide, bone-specific alkaline phosphatase and osteocalcin in the assessment of bone status in postmenopausal women.
    Trento LK; Pietropolli A; Ticconi C; Gravotta E; De Martino MU; Fabbri A; Piccione E
    J Obstet Gynaecol Res; 2009 Feb; 35(1):152-9. PubMed ID: 19215563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
    Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Marques-Neto JF; Weryha G; Verbruggen N; Hustad CM; Mahlis EM; Melton ME
    Int J Clin Pract; 2008 Apr; 62(4):575-84. PubMed ID: 18324951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
    Delmas PD; McClung MR; Zanchetta JR; Racewicz A; Roux C; Benhamou CL; Man Z; Eusebio RA; Beary JF; Burgio DE; Matzkin E; Boonen S
    Bone; 2008 Jan; 42(1):36-42. PubMed ID: 17920005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover.
    Borah B; Ritman EL; Dufresne TE; Jorgensen SM; Liu S; Sacha J; Phipps RJ; Turner RT
    Bone; 2005 Jul; 37(1):1-9. PubMed ID: 15894527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial.
    Anastasilakis AD; Goulis DG; Polyzos SA; Gerou S; Koukoulis G; Kita M; Avramidis A
    Horm Metab Res; 2008 Apr; 40(4):281-5. PubMed ID: 18275008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term risedronate treatment in postmenopausal women: effects on biochemical markers of bone turnover.
    Raisz L; Smith JA; Trahiotis M; Fall P; Shoukri K; Digennaro J; Sacco-Gibson N
    Osteoporos Int; 2000; 11(7):615-20. PubMed ID: 11069196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of risedronate on bone metabolism after total hip arthroplasty: a prospective randomised study.
    Kinov P; Tivchev P; Doukova P; Leithner A
    Acta Orthop Belg; 2006 Jan; 72(1):44-50. PubMed ID: 16570894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility of simultaneous measurement of bone formation and bone resorption markers to assess bone turnover rate in postmenopausal women: an EPOLOS study.
    Łukaszkiewicz J; Karczmarewicz E; Płudowski P; Jaworski M; Czerwiński E; Lewiński A; Marcinowska-Suchowierska E; Milewicz A; Spaczyński M; Lorenc RS;
    Med Sci Monit; 2008 Dec; 14(12):PH65-70. PubMed ID: 19043376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography.
    Borah B; Dufresne TE; Ritman EL; Jorgensen SM; Liu S; Chmielewski PA; Phipps RJ; Zhou X; Sibonga JD; Turner RT
    Bone; 2006 Aug; 39(2):345-52. PubMed ID: 16571382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
    J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of risedronate on high-dose corticosteroid-induced bone loss in patients with glomerular disease.
    Kikuchi Y; Imakiire T; Yamada M; Saigusa T; Hyodo T; Kushiyama T; Higashi K; Hyodo N; Yamamoto K; Suzuki S; Miura S
    Nephrol Dial Transplant; 2007 Jun; 22(6):1593-600. PubMed ID: 17041001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.
    Palomba S; Manguso F; Orio F; Russo T; Oppedisano R; Sacchinelli A; Falbo A; Tolino A; Zullo F; Mastrantonio P
    Menopause; 2008; 15(4 Pt 1):730-6. PubMed ID: 18698280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.